首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Interlaboratory Study of Quality Control Isolates for a Broth Microdilution Method (Modified CLSI M38-A) for Testing Susceptibilities of Dermatophytes to Antifungals
【2h】

Interlaboratory Study of Quality Control Isolates for a Broth Microdilution Method (Modified CLSI M38-A) for Testing Susceptibilities of Dermatophytes to Antifungals

机译:用于微量皮肤稀释法(改良的CLSI M38-A)的质量控制分离物的实验室间研究用于测试皮肤癣菌对真菌的敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards, or NCCLS) M38-A standard for the susceptibility testing of filamentous fungi does not specifically address the testing of dermatophytes. In 2003, a multicenter study investigated the reproducibility of the microdilution method developed at the Center for Medical Mycology, Cleveland, Ohio, for testing the susceptibility of dermatophytes. Data from that study supported the introduction of this method for testing dermatophytes in the future version of the CLSI M38-A standard. In order for the method to be accepted by CLSI, appropriate quality control isolates needed to be identified. To that end, an interlaboratory study, involving the original six laboratories plus two additional sites, was conducted to evaluate potential candidates for quality control isolates. These candidate strains included five Trichophyton rubrum strains known to have elevated MICs to terbinafine and five Trichophyton mentagrophytes strains. Antifungal agents tested included ciclopirox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole. Based on the data generated, two quality control isolates, one T. rubrum isolate and one T. mentagrophytes isolate, were identified and submitted to the American Type Culture Collection (ATCC) for inclusion as reference strains. Ranges encompassing 95.2 to 97.9% of all data points for all seven drugs were established.
机译:临床和实验室标准协会(CLSI;前全国临床实验室标准委员会,或NCCLS)M38-A对丝状真菌敏感性测试的标准并未专门针对皮肤真菌的测试。 2003年,一项多中心研究调查了在俄亥俄州克利夫兰的医学真菌学中心开发的微稀释方法的可重复性,该方法用于检测皮肤癣菌的敏感性。该研究的数据支持在将来的CLSI M38-A标准版本中引入此方法来测试皮肤癣菌。为了使该方法为CLSI所接受,需要确定适当的质量控制隔离物。为此,进行了一项实验室间研究,涉及最初的六个实验室以及两个其他地点,以评估可能的质量控制分离株候选者。这些候选菌株包括五种已知对特比萘芬具有提高的MIC的红毛癣菌菌株和五种毛状癣菌菌株。测试的抗真菌剂包括环吡酮,氟康唑,灰黄霉素,伊曲康唑,泊沙康唑,特比萘芬和伏立康唑。根据产生的数据,鉴定出两种质量控制分离株,一种为红曲霉分离株,另一种为薄荷生苔藓植物分离株,并提交给美国典型培养物保藏中心(ATCC)作为参考菌株。确定了涵盖所有七种药物的所有数据点的95.2%至97.9%的范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号